Fisher & Paykel Healthcare Beheer
Beheer criteriumcontroles 3/4
De CEO Fisher & Paykel Healthcare is Lewis Gradon, benoemd in Apr2016, heeft een ambtstermijn van 8.58 jaar. De totale jaarlijkse vergoeding van { bedraagt NZ$ 3.53M, bestaande uit 50.6% salaris en 49.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.098% van de aandelen van het bedrijf, ter waarde NZ$ 21.22M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.5 jaar en 4.5 jaar.
Belangrijke informatie
Lewis Gradon
Algemeen directeur
NZ$3.5m
Totale compensatie
Percentage CEO-salaris | 50.6% |
Dienstverband CEO | 8.6yrs |
Eigendom CEO | 0.1% |
Management gemiddelde ambtstermijn | 3.5yrs |
Gemiddelde ambtstermijn bestuur | 4.5yrs |
Recente managementupdates
Recent updates
The Returns On Capital At Fisher & Paykel Healthcare (NZSE:FPH) Don't Inspire Confidence
Oct 28Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) Shares May Have Run Too Fast Too Soon
Oct 08Here's Why Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) CEO Compensation Is The Least Of Shareholders Concerns
Aug 21Is Fisher & Paykel Healthcare (NZSE:FPH) A Risky Investment?
Jul 29Fisher & Paykel Healthcare (NZSE:FPH) Will Want To Turn Around Its Return Trends
Jul 11Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Investors Are Less Pessimistic Than Expected
Jun 22There May Be Reason For Hope In Fisher & Paykel Healthcare's (NZSE:FPH) Disappointing Earnings
Jun 05Is Fisher & Paykel Healthcare (NZSE:FPH) Using Too Much Debt?
Mar 27Be Wary Of Fisher & Paykel Healthcare (NZSE:FPH) And Its Returns On Capital
Feb 22Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) Business Is Yet to Catch Up With Its Share Price
Feb 05Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Shares Could Be 31% Above Their Intrinsic Value Estimate
Jan 03We Think Fisher & Paykel Healthcare (NZSE:FPH) Can Stay On Top Of Its Debt
Nov 30Fisher & Paykel Healthcare (NZSE:FPH) Could Be Struggling To Allocate Capital
Nov 12Estimating The Fair Value Of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH)
Aug 28Be Wary Of Fisher & Paykel Healthcare (NZSE:FPH) And Its Returns On Capital
Aug 10Here's Why Fisher & Paykel Healthcare (NZSE:FPH) Can Manage Its Debt Responsibly
Jul 02Be Wary Of Fisher & Paykel Healthcare (NZSE:FPH) And Its Returns On Capital
May 01Returns On Capital Signal Tricky Times Ahead For Fisher & Paykel Healthcare (NZSE:FPH)
Jan 23Does Fisher & Paykel Healthcare (NZSE:FPH) Have A Healthy Balance Sheet?
Dec 27Calculating The Fair Value Of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH)
Oct 28Shareholders Are Optimistic That Fisher & Paykel Healthcare (NZSE:FPH) Will Multiply In Value
Oct 13Fisher & Paykel Healthcare (NZSE:FPH) Has A Pretty Healthy Balance Sheet
Sep 28Calculating The Fair Value Of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH)
Jul 24A Look Into Fisher & Paykel Healthcare's (NZSE:FPH) Impressive Returns On Capital
Jul 10Fisher & Paykel Healthcare (NZSE:FPH) Seems To Use Debt Quite Sensibly
Jun 12A Look At The Fair Value Of Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH)
Apr 17Fisher & Paykel Healthcare (NZSE:FPH) Could Become A Multi-Bagger
Apr 04Does Fisher & Paykel Healthcare (NZSE:FPH) Have A Healthy Balance Sheet?
Mar 06With EPS Growth And More, Fisher & Paykel Healthcare (NZSE:FPH) Is Interesting
Jan 22Why The 41% Return On Capital At Fisher & Paykel Healthcare (NZSE:FPH) Should Have Your Attention
Dec 26Is Fisher & Paykel Healthcare (NZSE:FPH) A Risky Investment?
Dec 05This Is The Reason Why We Think Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) CEO Deserves A Bump Up To Their Compensation
Aug 11Is Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Worth NZ$31.6 Based On Its Intrinsic Value?
Aug 01Do Fisher & Paykel Healthcare's (NZSE:FPH) Earnings Warrant Your Attention?
Jul 07Is Fisher & Paykel Healthcare (NZSE:FPH) A Risky Investment?
Jun 24Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Mar 31 2024 | NZ$4m | NZ$2m | NZ$133m |
Dec 31 2023 | n/a | n/a | NZ$197m |
Sep 30 2023 | n/a | n/a | NZ$262m |
Jun 30 2023 | n/a | n/a | NZ$256m |
Mar 31 2023 | NZ$3m | NZ$2m | NZ$250m |
Dec 31 2022 | n/a | n/a | NZ$251m |
Sep 30 2022 | n/a | n/a | NZ$251m |
Jun 30 2022 | n/a | n/a | NZ$314m |
Mar 31 2022 | NZ$4m | NZ$2m | NZ$377m |
Dec 31 2021 | n/a | n/a | NZ$449m |
Sep 30 2021 | n/a | n/a | NZ$521m |
Jun 30 2021 | n/a | n/a | NZ$522m |
Mar 31 2021 | NZ$4m | NZ$2m | NZ$524m |
Dec 31 2020 | n/a | n/a | NZ$458m |
Sep 30 2020 | n/a | n/a | NZ$392m |
Jun 30 2020 | n/a | n/a | NZ$339m |
Mar 31 2020 | NZ$3m | NZ$1m | NZ$287m |
Dec 31 2019 | n/a | n/a | NZ$260m |
Sep 30 2019 | n/a | n/a | NZ$233m |
Jun 30 2019 | n/a | n/a | NZ$221m |
Mar 31 2019 | NZ$3m | NZ$1m | NZ$209m |
Dec 31 2018 | n/a | n/a | NZ$208m |
Sep 30 2018 | n/a | n/a | NZ$206m |
Jun 30 2018 | n/a | n/a | NZ$198m |
Mar 31 2018 | NZ$2m | NZ$993k | NZ$190m |
Compensatie versus markt: De totale vergoeding ($USD 2.06M ) Lewis } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de NZ markt ($USD 4.40M ).
Compensatie versus inkomsten: De beloning van Lewis is het afgelopen jaar met meer dan 20% gestegen, terwijl de winst van het bedrijf met meer dan 20% is gedaald.
CEO
Lewis Gradon (63 yo)
8.6yrs
Tenure
NZ$3,533,971
Compensatie
Mr. Lewis G. Gradon has been the Chief Executive Officer, Managing Director & Executive Director at Fisher & Paykel Healthcare Corporation Limited since April 1, 2016. He served as the Senior Vice Presiden...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
MD, CEO & Executive Director | 8.6yrs | NZ$3.53m | 0.098% NZ$ 21.2m | |
Chief Financial Officer | 5.7yrs | geen gegevens | 0.0045% NZ$ 981.3k | |
COO & GM of Respiratory Humidification | less than a year | geen gegevens | 0.00060% NZ$ 130.0k | |
Vice President of Products & Technology | 8.6yrs | geen gegevens | 0.019% NZ$ 4.1m | |
Head of Capital Markets & Investor Relations | no data | geen gegevens | geen gegevens | |
Company Secretary & General Counsel | less than a year | geen gegevens | geen gegevens | |
Senior Communications & Investor Relations Manager | no data | geen gegevens | geen gegevens | |
VP of Sales & Marketing and President of North America & Europe | less than a year | geen gegevens | 0.029% NZ$ 6.2m | |
Vice President of Human Resources | 4.1yrs | geen gegevens | geen gegevens | |
Vice President of Supply Chain | 2.8yrs | geen gegevens | geen gegevens | |
Vice President of Corporate | no data | geen gegevens | geen gegevens | |
General Manager of Airvo Optiflow | no data | geen gegevens | geen gegevens |
3.5yrs
Gemiddelde duur
Ervaren management: Het managementteam van FPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
MD, CEO & Executive Director | 8.6yrs | NZ$3.53m | 0.098% NZ$ 21.2m | |
Non-Executive Director | 23yrs | NZ$188.15k | 0.15% NZ$ 33.3m | |
Independent Chairman of the Board | 6yrs | NZ$220.74k | 0.0013% NZ$ 275.1k | |
Independent Non-Executive Director | 3.1yrs | NZ$212.77k | 0.0023% NZ$ 500.4k | |
Member of EcoDesign Advisory Board | no data | geen gegevens | geen gegevens | |
Non-Executive Director | less than a year | geen gegevens | geen gegevens | |
Non-Executive Independent Director | 1.1yrs | NZ$93.48k | 0.00032% NZ$ 69.3k | |
Independent Non-Executive Director | 7.4yrs | NZ$179.08k | 0.00065% NZ$ 140.8k | |
Independent Non-Executive Director | 2.4yrs | NZ$160.13k | 0.00033% NZ$ 71.5k | |
Member of EcoDesign Advisory Board | no data | geen gegevens | geen gegevens | |
Member of EcoDesign Advisory Board | no data | geen gegevens | geen gegevens | |
Member of EcoDesign Advisory Board | no data | geen gegevens | geen gegevens |
4.5yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van FPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).